

2021 Annual Breast Carcinoma Result Comparison Report

Tests Performed by Summit Pathology

The following tables summarize results from tests performed and read by Summit Pathology for all clients. All tests were performed and interpreted by Summit Pathology unless noted otherwise in the summary tables.

Estrogen and Progesterone Receptor Testing

Estrogen Receptor IHC Results

	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	200	18.55%	61	21.71%	139	17.44%
Positive	878	81.45%	220	78.29%	658	82.56%

¹ Estrogen receptor negative benchmark is at or below 30%

² Women 55 and older were classified as postmenopausal.

Progesterone Receptor IHC Results

	All Results		Premenopausal		Postmenopausal	
	n	Percentage ¹	n	Percentage	n	Percentage ²
Negative	327	30.53%	80	28.57%	247	31.23%
Positive	744	69.47%	200	71.43%	544	68.77%

¹ Progesterone receptor negative benchmark is 10-15% greater than estrogen receptor negative results.

² Women 55 and older were classified as postmenopausal.

Estrogen and Progesterone Receptor Negative Results: Special Types and Well-differentiated Carcinomas

Classification	Results	Estrogen Receptor Negative		Progesterone Receptor Negative	
		n	Percentage	n	Percentage
Lobular	119	2	1.68%	23	19.33%
Mucinous	21	0	0.00%	2	9.52%
Tubular	14	0	0.00%	2	14.29%
Tubulolobular	2	0	0.00%	0	0.00%
Well-differentiated	382	4	1.05%	44	11.52%

HER2/neu Testing

	All Grades		Low Grade		Intermediate Grade		High Grade	
	n	Percentage ¹	n	Percentage	n	Percentage	n	Percentage
Equivocal	1	0.14%	1	0.37%	—	—	—	—
Negative	617	85.34%	265	98.51%	250	81.43%	102	69.39%
Positive	105	14.52%	3	1.12%	57	18.57%	45	30.61%

¹ Benchmark for overall HER2/neu results is 10-25% positive.

Summary statistics represent combined IHC and amplification study results.

Additional Laboratory-wide results from HER2/neu testing in 2021

Frequency of HER2 equivocal carcinomas:

IHC scores of 2+ were found in 25.14% (398) of 1583 HER2/neu carcinomas.

Frequency of ISH positive results in HER2/neu equivocal (IHC=2+) carcinomas

12.2% (30) of 246 HER2/neu equivocal carcinomas (IHC=2+) were also ISH positive.

Frequency of HER2/neu positive carcinomas (IHC=3+)

IHC scores of 3+ were found in 8.21% (130) of 1583 HER2/neu carcinomas.

Comments by Medical Director

Medical Director : _____

Date: _____